Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 5Neoplasms 3Ovarian Neoplasms 2Solid Tumors 1Solid Cancers 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma 1

Interventions

Paclitaxel 12Gemcitabine 9atezolizumab 8Carboplatin 8Bevacizumab 6tocilizumab 4navitoclax 4liposomal doxorubicin 4Irinotecan 4Erlotinib Hydrochloride 4Cetuximab 4Sunitinib 3Oxaliplatin 3Leucovorin 3Injections 3Fluorouracil 3Docetaxel 3Cyclophosphamide 3tumor necrosis factor-alpha, CNGRC fusion protein, human 2tislelizumab 2temsirolimus 2ridaforolimus 2plocabulin 2pembrolizumab 2pazopanib 2olaparib 2obinutuzumab 2linifanib 2fludarabine 2envafolimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Solid Tumors × ipatasertib × Clear all
NCT04341259 2023-05-08

A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors.

Hoffmann-La Roche

Phase 1 Completed
12 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡